Delysid
E1020535
Delysid was the trade name under which the psychedelic drug LSD was originally marketed for psychiatric and experimental use in the mid-20th century.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
psychedelic drug
ⓘ
trade name ⓘ |
| activeIngredient | lysergic acid diethylamide ⓘ |
| brandStatus | discontinued ⓘ |
| chemicalSubstance | C20H25N3O ⓘ |
| countryOfOrigin | Switzerland ⓘ |
| developedBy | Sandoz Laboratories NERFINISHED ⓘ |
| firstMarketedBy | Sandoz GENERATED ⓘ |
| formulation |
ampoules
ⓘ
tablets ⓘ |
| hasEffect |
altered perception
ⓘ
cognitive changes ⓘ hallucinations ⓘ mood changes ⓘ |
| historicalUsePeriod | mid-20th century ⓘ |
| indicatedUse |
experimental psychiatry
ⓘ
model psychosis induction ⓘ psychotherapy adjunct ⓘ |
| introducedForUse |
clinical psychiatry
ⓘ
experimental psychotherapy ⓘ psychiatric research ⓘ |
| introducedInDecade | 1940s ⓘ |
| isSameAs | Sandoz LSD preparation NERFINISHED ⓘ |
| legalStatus | withdrawn from medical market ⓘ |
| manufacturer | Sandoz Laboratories NERFINISHED ⓘ |
| mechanismOfAction | 5-HT2A receptor agonist ⓘ |
| pharmacologicalClass |
ergoline derivative
ⓘ
serotonergic psychedelic ⓘ |
| regulatoryOutcome | subject to international control under UN drug conventions ⓘ |
| relatedConcept |
hallucinogens
ⓘ
psychedelic therapy ⓘ psychotomimetic agents ⓘ |
| risk |
acute anxiety reactions
ⓘ
precipitation of psychosis in vulnerable individuals ⓘ psychological distress ⓘ |
| routeOfAdministration |
intramuscular injection
ⓘ
intravenous injection ⓘ oral ⓘ |
| tradeNameOf |
LSD
NERFINISHED
ⓘ
lysergic acid diethylamide ⓘ |
| typicalDoseRange | 25 micrograms to 100 micrograms ⓘ |
| usedAs |
tool for studying consciousness
ⓘ
tool for studying schizophrenia ⓘ |
| usedBy |
clinical researchers
ⓘ
psychiatrists ⓘ psychotherapists ⓘ |
| withdrawnInDecade | 1960s ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.